NEW YORK (GenomeWeb News) – Drug developer Boehringer Ingelheim and synthetic biology company GeneArt will collaborate to develop DNA-based pharmaceutical agents for clinical trials that both companies will market, GeneArt said today.
 
Under the agreement, GeneArt will use Boehringer Ingelheim’s technology to produce and purify plasmid DNA for use in research and for commercial purposes, and Boehringer Ingelheim will produce plasmids for the subsequent clinical trials and for sale globally.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.

An opinion piece at Bloomberg discusses China's stance on genomic research.

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.